COMMUNIQUÉS West-GlobeNewswire
-
PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
11/03/2026 -
Albanian-Finnish Startup Bliss Raises $270K to Build Culturally Intelligent AI for Therapy
11/03/2026 -
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
11/03/2026 -
Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention
11/03/2026 -
KOMO Biosciences Grants Research Evaluation License to Syngenta to Explore Precision Genome Modification in Maize
11/03/2026 -
MAPS, in Partnership with the Shulgin Foundation, Launches Music Is the Bridge Video Series; First Episode Features Reggie Watts and Hamilton Morris
11/03/2026 -
Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite
11/03/2026 -
Inc. Names Commure’s Deepika Bodapati to Its 2026 Female Founders 500 List
11/03/2026 -
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
11/03/2026 -
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11/03/2026 -
Catheter Precision, Inc. Secures up to $88 Million in Strategic Institutional Financing Commitments to Fund Accelerated Growth
11/03/2026 -
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
11/03/2026 -
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy
11/03/2026 -
Sanara MedTech Inc. Announces Publication of Peer-Reviewed Study Evaluating the Economic and Clinical Value of CellerateRX® Surgical Powder in the Management of Spine Surgery Wounds
11/03/2026 -
La Commission européenne approuve AKEEGA® (comprimé à double action de niraparib et d’acétate d’abiratérone) pour le traitement des patients atteints d’un cancer de la prostate hormonosensible métastatique (CPHSm) présentant des mutations BRCA1/2
11/03/2026 -
BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
11/03/2026 -
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
11/03/2026 -
Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board
11/03/2026 -
AiM Medical Robotics adds surgical robotics pioneer, Dr. Yulun Wang, to its world-class Board
11/03/2026
Pages